振德医疗回应股价异动，称生产经营正常无未披露重大信息

Company Situation - The company confirmed that its production and operations are normal, with no significant changes in the external business environment or industry policies [3] - The only major disclosure required recently is the change in the purpose of share repurchase and cancellation, involving 1,959,310 shares, which has been approved by the board and temporary shareholders' meeting [3] - The company, its controlling shareholders, and actual controllers confirmed that there are no other undisclosed significant information, including major asset restructuring, issuance of shares, or acquisitions [3] Stock Performance - The company's stock price experienced a cumulative increase of over 20% during three consecutive trading days on February 6, 9, and 10, 2026, triggering an abnormal trading situation as per the Shanghai Stock Exchange [2] - As of February 11, 2026, the stock closed at 92.20 yuan, with a single-day increase of 3.88%, continuing to rise after two consecutive days of hitting the upper limit [2] Industry Context - Prior to the stock price fluctuations, the market had focused on the event where Sun Jimu acquired a 5% stake in the company in September 2025, and the company's net profit for the first three quarters of 2025 decreased by 33.91%, although the third quarter's non-recurring net profit increased by 2.0% year-on-year [4] - The company emphasized in its latest announcement that these were all disclosed information and not the undisclosed reasons for the recent abnormal fluctuations [4]